Sarepta licenses five LGMD gene therapy candidates from Myonexus; has option to buy company, later exercised
Sarepta Therapeutics Inc. licensed exclusive rights to five of Myonexus Therapeutics Inc.'s gene therapy pipeline programs in limb-girdle muscular dystrophies (LGMDs).
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Includes M&A Option
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.